Optimizing treatment of HER2-positive metastatic breast cancer

被引：6

作者：

Jones, AL

Leyland-Jones, B

机构：

[1] Royal Free Hosp, Dept Oncol, London NW3 2QG, England

[2] McGill Comprehens Canc Ctr, Montreal, PQ, Canada

来源：

SEMINARS IN ONCOLOGY | 2004年 / 31卷 / 05期

关键词：

D O I：

10.1053/j.seminoncol.2004.07.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：29 / 34

页数：6

共 18 条

[1]

[Anonymous], 2003, CANC FACTS FIG

[2] Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) in patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC) [J].

Baselga, J. ;

Climent, M. A. ;

Lluch, A. ;

Hornedo, J. ;

Gascon, R. ;

Sanchez, A. T. ;

Guillem, V. ;

Cortes-Funes, H. ;

Regueiro, P. ;

Trigo, J. .

EJC SUPPLEMENTS, 2004, 2 (03) :132-132

[3] Maximizing clinical benefit with trastuzumab [J].

Bell, R ;

Verma, S ;

Untch, M ;

Cameron, D ;

Smith, I .

SEMINARS IN ONCOLOGY, 2004, 31 (05) :35-44

[4] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[5] Retrospective analysis of the safety of Herceptin® immunotherapy in metastatic breast cancer [J].

Cook-Bruns, N .

ONCOLOGY, 2001, 61 :58-66

[6] Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC):: results of a randomised multicentre trial [J].

Extra, J. M. ;

Cognetti, F. ;

Maraninch, D. ;

Snyder, R. ;

Mauriac, L. ;

Tubiana-Hulin, M. ;

Chan, S. ;

Grimes, D. ;

Anton, A. ;

Marty, M. .

EJC SUPPLEMENTS, 2004, 2 (03) :125-126

[7]

Ferlay J., 2001, GLOBOCAN 2000 CANC I

[8]

Ghahramani P., 2003, Breast, V12, pS40, DOI 10.1016/S0960-9776(03)80128-5

[9] Prospective investigation of the significance of cardiac markers, NT-pro Brain Natriuretic Peptide (NT-proBNP) and Troponin T (TnT), in the HERCULES study of epirubicin/cyclophosphamide with or without trastuzumab (Herceptin®) [J].

Langer, B. ;

Muscholl, M. ;

Pauschinger, M. ;

Thomssen, C. ;

Eidtmann, H. ;

Untch, M. ;

Meerpohl, H. G. ;

du Bois, A. ;

Weber, H. ;

Lueck, H. J. .

EJC SUPPLEMENTS, 2004, 2 (03) :143-143

[10] Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel [J].

Leyland-Jones, B ;

Gelmon, K ;

Ayoub, JP ;

Arnold, A ;

Verma, S ;

Dias, R ;

Ghahramani, P .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3965-3971

← 1 2 →